[1] Brunt EM. Pathology of nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol,2010,7: 195-203.
[2] Vernon G,Baranova A,Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther, 2011, 34:274-285.
[3] Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of liver diseases,American College of Gastroenterology,and t-he American Gastroenterological Association. Hepatology, 2012, 55:2005-2023.
[4] Musso G,Gambino R,Cassader M,et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011, 43:617-649.
[5] Hossain N,Afendy A,Stepanova M,et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.Clinical Gastroenterology Hepatology, 2009, 7:1224-1229,1229: e1-e2.
[6] Verma S,Jensen D,Hart J,et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).Liver Int, 2013, 33:1398-1405.
[7] Angulo P,Keach JC,Batts KP,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.Hepatology,1999, 30:1356-1362.
[8] Kruger FC,Daniels CR,Kidd M,et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH.S Afr Med,2011,101:477-480.
[9] Kowdley KV,Belt P,Wilson LA,et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2012, 55:77-85.
[10] Angulo P,Hui JM,Marchesini G,et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45:846-854.
[11] Harrison SA,Oliver D,Arnold HL,et al.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut,2008, 57:1441- 1447.
[12] Shah AG,Lydecker A,Murray K,et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2009, 7:1104-1112
[13] Demir M,Lang S,Schlattjan M,et al.NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.Plos One, 2013, 8:e58360.
[14] Guha IN,Parkes J,Roderick P,et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers.Hepatology, 2008, 47:455-460.
[15] Adams LA,Bulsara M,Rossi E,et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.Clin Chem, 2005, 51:1867-1873
[16] Calès P,Lainé F,Boursier J,et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. Hepatol, 2009, 50:165-173.
[17] Ratziu V,Massard J,Charlotte F,et al.Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 2006, 6:6.
[18] Adams LA,George J,Bugianesi E,et al.Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.Gastroenterol Hepatol, 2011, 26:1536-1543.
[19] Castera L,Vilgrain V,Angulo P. Noninvasive evaluation of NAFLD.Nat Rev Gastroenterol Hepatol, 2013, 10: 666-675.
[20] Ratziu V,Bellentani S,Cortez-Pinto H,et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference.Hepatol, 2010, 53: 372-384.
[21] Demir M,Lang S,Nierhoff D,et al.Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. Clin Gastroenterol, 2013, 47: 719-726.
[22] Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C.Gastroenterology, 2012, 142: 1293-1302.e4.
[23] Wong VW,Vergniol J,Wong GL. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.Hepatology, 2010, 51:454-462.
[24] Wong VW,Vergniol J,Wong GL,et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease.Am Gastroenterol, 2012, 107:1862-1871.
[25] Petta S,Di Marco V,Cammà C,et al.Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index.Aliment Pharmacol Ther, 2011, 33:1350-1360.
[26] Myers RP,Pomier-Layrargues G,Kirsch R,et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology, 2012, 55:199-208.
[27] Festi D,Schiumerini R,Marzi L,et al. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods.Aliment Pharmacol Ther, 2013, 37: 392-400.
[28] Haixia Liu,Jing Fu,Ruixia Hong,et al.Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis. PLoS One, 2015, 10: e0127782.
[29] Cui J,Ang B,Haufe W,et al.Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.Alimentary pharmacology and therapeutics, 2015, 15:13196.
[30] Jérôme Boursier,Julien Vergniol,Anne Guillet, et al.Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by Fibroscan in non-alcoholic fatty liver disease.Journal of hepatology, 2016, 4: 23. |
